



## Announcement Summary

---

**Entity name**

BIOXYNE LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

Monday May 22, 2023

**The +securities to be quoted are:**

Other

**Total number of +securities to be quoted**

ASX +security code	Security description	Number of +securities to be quoted	Issue date
BXN	ORDINARY FULLY PAID	1,230,000,000	19/05/2023

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

BIOXYNE LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

**1.2 Registered number type**

ABN

**Registration number**

97084464193

**1.3 ASX issuer code**

BXN

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

22/5/2023

For personal use only



Part 2 - Type of Issue

---

**2.1 The +securities to be quoted are:**

Other

**2.2 The +securities to be quoted are:**

Additional +securities in a class that is already quoted on ASX ("existing class")

**2.3c Have these +securities been offered under a +disclosure document or +PDS?**

No

**2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B**

Securities issued as consideration for the acquisition of Breathe Life Sciences - see

[https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02652230-2A1442327?access\\_token=83ff96335c2d45a094df02a206a39ff4](https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02652230-2A1442327?access_token=83ff96335c2d45a094df02a206a39ff4)

**2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:**

Not applicable - the entity has arrangements in place with the holder that ensure the securities cannot be on-sold within 12 months in a manner that would breach section 707(3) or 1012C(6)



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

**Additional +securities to be quoted in an existing class**

**ASX +security code and description**

BXN : ORDINARY FULLY PAID

**Issue date**

19/5/2023

**Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

Issue details

**Number of +securities to be quoted**

1,230,000,000

**Are the +securities being issued for a cash consideration?**

No

**Please describe the consideration being provided for the +securities**

Securities Issued as consideration for the acquisition of Breathe Life Sciences

**Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted**

0.030000

**Any other information the entity wishes to provide about the +securities to be quoted**

See Notice of Meeting lodged with ASX on 6 April 2023 and results of shareholder meeting on 5 May 2023. The shares issued are subject to a voluntary escrow until 19 May 2024.

**The purpose(s) for which the entity is issuing the securities**

To pay for the acquisition of an asset

**Please provide additional details**

[https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02652230-2A1442327?access\\_token=83ff96335c2d45a094df02a206a39ff4](https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02652230-2A1442327?access_token=83ff96335c2d45a094df02a206a39ff4)



Part 4 - Issued capital following quotation

---

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

**4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
BXN : ORDINARY FULLY PAID	1,895,645,398

**4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
---	---

For personal use only



Part 5 - Other Listing Rule requirements

---

**5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?**

No

**5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?**

Yes

**5.2a Date of meeting or proposed meeting to approve the issue under listing rule 7.1**

5/5/2023

For personal use only